The Impact of Digital Technologies in Transforming and Accelerating Vaccine Trials, Development and Delivery

, , , , , , ,


 

 

The Impact of Digital Technologies in Transforming and Accelerating Vaccine Trials, Development and Delivery

Lessons from COVID-19

WEDNESDAY, FEBRUARY 17, 2021

12:00 P.M. – 1:00 P.M. ET

REGISTER

 

Even before the full impact of the COVID-19 pandemic was understood, public and private sector leaders mobilized to accelerate the development, approval and production of vaccines to safeguard the world against the devastating virus. In less than a year, several vaccines emerged and demonstrated high efficacy in preventing COVID-19 infections. Many factors contributed to the unprecedented speed with which these vaccines were made available for use, but the role played by digital technologies, including AI, was particularly critical.

As a preview of discussions planned for the October 28-29, 2021 Galien Forum, the Galien Foundation is hosting a webinar series that will explore the game-changing role that Digital Technologies, including Artificial Intelligence (AI), play in today’s clinical trials, with a focus on the development of the COVID-19 vaccines.

This Galien Foundation’s webinar will feature leaders from the pharmaceutical companies that drove this historic global health success story, including:

  • Jessica Federer (Moderator), Managing Director, Huma; Former CDO Bayer
  • Rachel Berria, VP & Medical Head, Astrazeneca US
  • Marie-Pierre Hellio Le Graverand, MD, DSc, PhD, SVP, Head of Clinical Development and Operations, Pfizer
  • Terry Murphy, COVID-19 Clinical Development Relaunch Leader, Janssen Pharmaceutical
  • Nagaraja Srivatsan, SVP & CDO, R&DS Technology Solutions, IQVIA
  • Tal Zacks, CMO, Moderna 

 

What role did Digital Technologies play in the development, clinical trials and production of the COVID-19 vaccines?

What specific technologies were most helpful in accelerating these phases and dramatically collapsing the vaccine development timeline?

What efficiencies were achieved by leveraging technologies in each area?

Which technologies worked well? Which did not? What lessons can we take from these experiences for future biomedical innovations?

 

/by